E-Therapeutics’ B4GALT1-targeting Galomic siRNA demonstrates prolonged duration of action
Nov. 28, 2024
Potent siRNAs against B4GALT1 were designed in silico and screened in vitro (Huh7 cells, primary mouse, human hepatocytes) as well as in vivo (C57BL/6 mice) for the selection of a lead Galomic siRNA.